Daniel‐Henri Caignard

1.8k total citations
62 papers, 1.6k citations indexed

About

Daniel‐Henri Caignard is a scholar working on Molecular Biology, Organic Chemistry and Endocrine and Autonomic Systems. According to data from OpenAlex, Daniel‐Henri Caignard has authored 62 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 38 papers in Organic Chemistry and 15 papers in Endocrine and Autonomic Systems. Recurrent topics in Daniel‐Henri Caignard's work include Synthesis and Biological Evaluation (15 papers), Circadian rhythm and melatonin (15 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (13 papers). Daniel‐Henri Caignard is often cited by papers focused on Synthesis and Biological Evaluation (15 papers), Circadian rhythm and melatonin (15 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (13 papers). Daniel‐Henri Caignard collaborates with scholars based in France, Belgium and Spain. Daniel‐Henri Caignard's co-authors include Pierre Renard, Bruno Pfeiffer, Philippe Delagrange, Sylvain Rault, Stéphane Léonce, Jean A. Boutin, Ghanem Atassi, Patrick Depreux, Daniel Lesieur and Béatrice Guardiola‐Lemaître and has published in prestigious journals such as Journal of Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and Tetrahedron.

In The Last Decade

Daniel‐Henri Caignard

62 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel‐Henri Caignard France	24	945	666	249	216	139	62	1.6k
Pascal Berthelot France	18	575 0.6×	546 0.8×	149 0.6×	147 0.7×	98 0.7×	96	1.1k
Pier Vincenzo Plazzi Italy	22	585 0.6×	533 0.8×	350 1.4×	279 1.3×	456 3.3×	50	1.5k
Mark T. Goulet United States	26	659 0.7×	710 1.1×	233 0.9×	183 0.8×	171 1.2×	54	1.6k
Antonio Entrena Spain	21	703 0.7×	500 0.8×	222 0.9×	70 0.3×	165 1.2×	60	1.5k
Anthony J. Roecker United States	20	881 0.9×	748 1.1×	444 1.8×	127 0.6×	280 2.0×	28	2.2k
Philip A. Hipskind United States	23	694 0.7×	913 1.4×	162 0.7×	617 2.9×	86 0.6×	41	2.2k
Darius P. Zlotos Germany	19	354 0.4×	610 0.9×	666 2.7×	265 1.2×	59 0.4×	66	1.4k
Giovanni Piersanti Italy	28	1.2k 1.3×	639 1.0×	59 0.2×	195 0.9×	502 3.6×	85	2.0k
James V. Heck United States	19	483 0.5×	614 0.9×	432 1.7×	76 0.4×	232 1.7×	30	1.6k
Giuseppe Diamantini Italy	21	472 0.5×	312 0.5×	354 1.4×	135 0.6×	75 0.5×	43	1.1k

Countries citing papers authored by Daniel‐Henri Caignard

Since Specialization

Citations

This map shows the geographic impact of Daniel‐Henri Caignard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel‐Henri Caignard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel‐Henri Caignard more than expected).

Fields of papers citing papers by Daniel‐Henri Caignard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel‐Henri Caignard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel‐Henri Caignard. The network helps show where Daniel‐Henri Caignard may publish in the future.

Co-authorship network of co-authors of Daniel‐Henri Caignard

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel‐Henri Caignard. A scholar is included among the top collaborators of Daniel‐Henri Caignard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel‐Henri Caignard. Daniel‐Henri Caignard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dacquet, Catherine, Nathalie Hennuyer, Bart Staels, et al.. (2017). Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression. European Journal of Medicinal Chemistry. 137. 310–326. 7 indexed citations

Rami, Marouan, et al.. (2017). Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT 1 /MT 2 ) and serotoninergic (5-HT 2C ) dual ligands. European Journal of Medicinal Chemistry. 141. 552–566. 13 indexed citations

Boutin, Jean A., Daniel‐Henri Caignard, Philippe Delagrange, et al.. (2015). Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives. European Journal of Medicinal Chemistry. 109. 360–370. 7 indexed citations

Díaz, Amelia, et al.. (2014). Synthesis of new melatoninergic hexahydroindenopyridines. Bioorganic & Medicinal Chemistry Letters. 24(15). 3534–3536. 4 indexed citations

Pérès, Basile, Jean A. Boutin, Daniel‐Henri Caignard, et al.. (2014). Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II). European Journal of Medicinal Chemistry. 90. 822–833. 9 indexed citations

Rami, Marouan, et al.. (2012). Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands. Molecules. 18(1). 154–166. 8 indexed citations

Rami, Marouan, Jean A. Boutin, Philippe Delagrange, et al.. (2012). Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). European Journal of Medicinal Chemistry. 49. 310–323. 31 indexed citations

Rami, Marouan, Amaury Farce, Jean A. Boutin, et al.. (2011). Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. European Journal of Medicinal Chemistry. 46(5). 1622–1629. 9 indexed citations

Pirotte, Bernard, Pierre Francotte, Eric Goffin, et al.. (2010). Ring-Fused Thiadiazines as Core Structures for the Development of Potent AMPA Receptor Potentiators. Current Medicinal Chemistry. 17(30). 3575–3582. 20 indexed citations

10.

Caignard, Daniel‐Henri, Nathalie Hennuyer, Bart Staels, et al.. (2009). 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. Bioorganic & Medicinal Chemistry Letters. 19(10). 2683–2687. 16 indexed citations

11.

Cruciani‐Guglielmacci, Céline, Nadim Kassis, Laurence Clément, et al.. (2009). S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. European Journal of Pharmacology. 608(1-3). 104–111. 9 indexed citations

12.

Francotte, Pierre, Pascal De Tullio, Tchao Podona, et al.. (2008). Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators. Bioorganic & Medicinal Chemistry. 16(23). 9948–9956. 23 indexed citations

13.

Vidaillac, Céline, Jean Guillon, Stéphane Moreau, et al.. (2007). Synthesis of new 4-[2-(alkylamino)ethylthio]pyrrolo[1,2- a ]quinoxaline and 5-[2-(alkylamino)ethylthio]pyrrolo[1,2- a ]thieno[3,2- e ]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 22(5). 620–631. 15 indexed citations

14.

Beauverger, Philippe, Marianne Rodriguez, Jean‐Paul Nicolas, et al.. (2004). Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay. Cellular Signalling. 17(4). 489–496. 2 indexed citations

15.

Lisowski, Vincent, Frédéric Fabis, Alain St. Pierre, et al.. (2002). Synthesis of New Aromatic Pyrrolo[2,1- c] [1,4]benzodiazepines and Pyrrolo[1,2- a] thieno[3,2- e] [1,4]diazepines as Anti-tumoral Agents. Journal of Enzyme Inhibition and Medicinal Chemistry. 17(6). 403–407. 19 indexed citations

16.

Anastassiadou, Maria, Saı̈da Danoun, G Baziard-Mouysset, et al.. (2001). Synthesis and pharmacological evaluation of imidazoline sites I1 and I2 selective ligands. Bioorganic & Medicinal Chemistry. 9(3). 585–592. 49 indexed citations

17.

Li, Ying, Feng Shan, Jinming Wu, et al.. (2001). Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorganic & Medicinal Chemistry Letters. 11(1). 5–8. 76 indexed citations

18.

Pfeiffer, Bruno, et al.. (1995). N-Substituted Oxazolo[5,4-b]pyridin-2(1H)-ones: A New Class of Non-Opiate Antinociceptive Agents. Journal of Medicinal Chemistry. 38(8). 1278–1286. 49 indexed citations

19.

Depreux, Patrick, Daniel Lesieur, Peter J. Morgan, et al.. (1994). Synthesis and Structure-Activity Relationships of Novel Naphthalenic and Bioisosteric Related Amidic Derivatives as Melatonin Receptor Ligands. Journal of Medicinal Chemistry. 37(20). 3231–3239. 125 indexed citations

20.

Podona, Tchao, Béatrice Guardiola‐Lemaître, Daniel‐Henri Caignard, et al.. (1994). 3,4-Dihydro-3-amino-2H-1-benzopyran Derivatives as 5-HT1A Receptor Ligands and Potential Anxiolytic Agents. 1. Synthesis and Structure-Activity Relationship Studies. Journal of Medicinal Chemistry. 37(12). 1779–1793. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact